HCP
RVMD icon

Hexagon Capital Partners’s Revolution Medicines RVMD Stock Holding History

Hexagon Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30
Closed -$1.31K – 1908
2024
Q4 		$1.31K Buy
+30
New +$1.51K ﹤0.01% 1500

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hexagon Capital Partners's RVMD Position: Q1 2025 in Review

Hexagon Capital Partners sold out of Revolution Medicines (RVMD) in Q1 2025, closing a stake of 30 shares — an estimated $1.31K sold.

Hexagon Capital Partners first reported a position in RVMD in Q4 2024 and held it in 1 quarter. The position peaked at $1.31K in Q4 2024. 284 funds tracked by Wall St. Rank hold RVMD as of Q1 2025.

  • Hexagon Capital Partners reported no remaining Revolution Medicines position as of Q1 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 30 Revolution Medicines shares in Q1 2025, an estimated $1.31K.
  • Hexagon Capital Partners first reported a position in Revolution Medicines in Q4 2024 and held it in 1 quarter.
  • Hexagon Capital Partners's Revolution Medicines position peaked at $1.31K in Q4 2024.
  • 284 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2025.

Based on Hexagon Capital Partners's 13F filing for Q1 2025, filed 29 Apr 2025.